Studying a hormone in the venom of this reptile species that may allow it to eat infrequently led to the weight-loss drug Ozempic
The March 9, 2026 episode of Jeopardy! featured a Final Jeopardy clue in the category “Reptiles” that connected zoology with modern medical research. The clue read: “Studying a hormone in the venom of this reptile species that may allow it to eat infrequently led to the weight-loss drug Ozempic.” The prompt challenged contestants to identify a reptile whose unusual biological traits helped inspire one of the most widely discussed medications in recent years.
The clue drew attention to the scientific origins behind Ozempic, a drug used to treat type 2 diabetes and widely known for its role in weight management. Researchers discovered that a hormone related to appetite regulation could be traced back to the venom of a particular reptile species. That discovery eventually led to the development of medications that mimic the hormone’s effects in the human body.
What is the Gila Monster?
The Gila monster is a venomous lizard native to the southwestern United States and northwestern Mexico. Known for its distinctive orange and black patterned skin and slow-moving nature, the reptile is one of only a few venomous lizards in the world. Although it is rarely dangerous to humans, the animal’s venom has attracted significant scientific interest over the years.
Researchers studying the Gila monster discovered that its venom contains a hormone called exendin-4. This compound is similar to a hormone in humans known as GLP-1, which helps regulate blood sugar levels and appetite. Scientists recognized that the hormone’s effects could have important medical applications, especially for conditions involving metabolism and glucose control.
How the Discovery Led to Modern Diabetes Treatments
The discovery of exendin-4 in the Gila monster’s venom led researchers to develop medications that mimic the hormone’s activity in the human body. One of the earliest drugs created from this research was exenatide, which became a treatment for type 2 diabetes. The medication works by stimulating insulin release, slowing digestion, and helping control blood sugar levels.
These findings opened the door for a new class of medications known as GLP-1 receptor agonists. Drugs in this category help regulate blood glucose and also influence appetite signals in the brain. Because they slow gastric emptying and promote a feeling of fullness, they can lead to reduced calorie intake and weight loss.
The Connection to Ozempic
Ozempic is one of the best-known medications in this GLP-1 drug class. Its active ingredient, semaglutide, works by mimicking the same biological pathway that scientists first explored after studying the Gila monster’s venom. While the medication itself is synthetic and not directly derived from the lizard’s venom, the scientific breakthrough that made it possible began with that research.
Today, Ozempic is prescribed primarily to manage type 2 diabetes by improving blood sugar control. However, the medication has gained widespread attention because it can also lead to significant weight loss. This secondary effect has led to related medications being approved specifically for weight management.
A Rare Reptile with an Unusual Scientific Legacy
The Gila monster’s role in the development of modern metabolic treatments highlights the unexpected ways in which animal biology can influence medical science. The reptile is known for its slow metabolism and ability to survive long periods between meals, a trait that first prompted scientists to investigate its hormones.
Although the Gila monster itself remains a relatively obscure desert reptile, its biological chemistry has played an important role in pharmaceutical research. The link between the reptile’s venom and modern GLP-1 medications demonstrates how studying unusual traits in wildlife can lead to breakthroughs that affect millions of people around the world.